Effects of C2-Alkylation, N-Alkylation, and N,N′-Dialkylation on the Stability and Estrogen Receptor Interaction of (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 915-927

  Von Rauch, Moriz ^a   Schlenk, Miriam ^a   Gust, Ronald ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIAMINO 1,2 BIS(4 METHOXYPHENYL)ETHANE; 4 (2 CHLORO 4 HYDROXYPHENYL) 5 (2,6 DICHLORO 4 HYDROXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4 (2 CHLORO 4 METHOXYPHENYL) 5 (2,6 DICHLORO 4 METHOXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 (2 HYDROXYETHYL) 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 METHOXYPHENYL) 2 (2 METHOXYETHYL) 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 METHOXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 METHOXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(2 FLUORO 4 HYDROXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(2 FLUORO 4 HYDROXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(2 FLUORO 4 METHOXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(2 FLUORO 4 METHOXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 (2 HYDROXYETHYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 METHYL 2 IMIDAZOLINE; 4,5 BIS(4 METHOXYPHENYL) 2 (2 METHOXYETHYL) 2 IMIDAZOLINE; 4,5 BIS(4 METHOXYPHENYL) 2 ETHYL 2 IMIDAZOLINE; 4,5 BIS(4 METHOXYPHENYL) 2 METHYL 2 IMIDAZOLINE; ESTER DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ETHANE; ETHER DERIVATIVE; IMIDAZOLINE DERIVATIVE; LUCIFERASE; N ETHYL 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; N METHYL 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; TETRAHYDROFURAN; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CELL STRAIN MCF 7; CYCLIZATION; DIASTEREOISOMER; GENE ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; CATTLE; CELL LINE, TUMOR; DRUG STABILITY; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYDROLYSIS; IMIDAZOLES; LUCIFERASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 0842347632     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0309809     Document Type: Article

References (26)

1. Korach, K. S.; Migliaccio, S.; Davis, V. L. Estrogens. In Principles of Pharmacology. Basic Concepts and Clinical Applications; Munson, P. L., Ed.; Chapman and Hall: New York, 1994; pp 809-825.
2. Turner, R. T.; Riggs, B. L.; Spelsberg, T. C. Skeletal effects of estrogens. Endocr. Rev. 1994, 15, 275-300.
3. Farhat, M. Y.; Lavigne, M. C.; Ramwell, P. W. The vascular protective effects of estrogen. FASEB J. 1996, 10, 615-624.
4. Iafrati, M., D.; Karas, R. H.; Aronovitz, M.; Kim, S.; Sullivan, T. R.; Lubahn, D. B.; O'Donnell, T. F.; Korach, K. S.; Mendelsohn, M. E. Estrogen inhibits the vascular injury response in estrogen receptor deficient mice. Nat. Med. 1997, 3, 545-548.
5. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. W.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J. Å.; Carlquist, M. Molecular Basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
6. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of agonism and antagonism in the oestrogen receptor. Cell 1998, 95, 927-937.
7. Pike, A. C. W.; Brzozowski, M.; Walton, J.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engström, O.; Ljunggren, J.; Gustafsson, J. Å.; Pike, M. C. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist a full antagonist. EMBO J. 1999, 18, 4608-4618.
8. Green, C. D. The molecular basis for functional differences between oestrogen receptor α and oestrogen receptor β. Recent Res. Dev. Steroid Biochem. Mol. Biol. 2000, 1, 19-26.
9. Gust, R.; Keilitz, R.; Schmidt, K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J. Med. Chem. 2001, 44, 1963-1970.
10. Gust, R.; Keilitz, R.; Schmidt, K.; von Rauch, M. (4R,5S)/(4S/5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: Ligands for the estrogen receptor with a novel binding mode. J. Med. Chem. 2002, 45, 3356-3365.
11. Gust, R.; Keilitz, R.; Schmidt, K. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines. J. Med. Chem. 2002, 45, 2325-2337.
12. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as functional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 2003, 46, 1081-1111.
13. Pinner, A. Ueber die Umwandlung der Nitrile in Imide (On the Transformation of Nitriles into Imides). Chem. Ber. 1883, 16, 1643-1655.
14. 2 symmetric imidazolines and tetrahydrofuran as electrophile. J. Org. Chem. 1998, 63, 8107-8117.
15. Watts, M. M. Imidazoline hydrolysis in alkaline and acidic media. A review. J. Am. Oil Chem. Soc. 1990, 67, 993-995.
16. de Savignac, A.; Kabbage, T.; Dupin, P.; Calmon, M. Etude cinétique de l'ouverture du cycle imidazoline par hydrolyse basique (Kinetic study of the opening of the imidazoline ring by basic hydrolysis). J. Heterocycl. Chem. 1978, 15, 897-905.
17. Hafner, F.; Holler, E.; von Angerer, E. Effect of growth factors on estrogen receptor mediated gene expression. J. Steroid Biochem. Mol. Biol. 1996, 58, 385-393.
18. Nilsson, S.; Makela, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J. A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81, 1535-1565.
19. Feigelson, H. S.; Henderson, B. E. Estrogens and breast cancer. Carcinogenesis 1996, 17, 2279-2284.
20. Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens: A review. Curr. Med. Chem. 1994, 1, 61-104.
21. Miller, C. P. SERMs: Evolutionary chemistry, revolutionary biology. Curr. Pharm. Des. 2002, 8, 2089-2111.
22. MacGregor Schafer, J.; Liu, H.; Bentrem, D. J.; Zapf, J. W.; Jordan, V. C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000, 60, 5097-5105.
23. Ekena, K.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Determinants of ligand specificity of estrogen receptor-α: estrogen versus androgen discrimination. J. Biol. Chem. 1998, 273, 693-699.
24. Kekenes-Huskey, P. M.; Muegge, I.; von Rauch, M.; Gust, R.; Knapp, E. W. A Molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophor. Bioorg. Med. Chem., submitted, 2003.
25. Poupaert, J. H.; Lambert, D. M.; Vamecq, J.; Abul-Hajj, Y. J. Molecular modeling studies on 11β-aminoethoxyphenyl and 7α-aminoethoxyphenyl estradiols. Evidence suggesting a common hydrophobic pocket in estrogen receptor. Bioorg. Med. Chem. Lett. 1995, 5, 839-842.
26. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.